Long Term Treatment Interruptions

NCT00433056 | Completed Phase 3

• 1 other identifier: LOTTI
• Study Type: interventional
• Target: 320
• Locations: 1 country
• Sites: 1

Brief Summary

LOTTI study Centers This a multicenter, multinational study. Clinical phase: III Objectives The primary objective is to compare efficacy and safety of continuing a conventional HAART in chronically infected HIV patients with a therapeutic strategy based on long term, immunologically driven treatment interruptions. Secondary objectives are:

• To verify the risk of developing viral resistance
• To verify the effect of the two strategies on metabolic parameters
• To verify the possibility to steadily discontinue antiretroviral therapy in patients who started it with baseline immunological values higher than those currently recommended by international guidelines for HIV treatment
• To identify predictive variables of the possibility to safely discontinue antiretroviral therapy
• To verify the dynamic of CD4+ cell loss and HIV replication after treatment interruption Number of Patients: A total of 320 patients. Study design: Controlled, Randomized, Open study The study will last 5 years Treatment arms: Patients will be randomized in a ratio 1:1 to one of the two treatment arms Control group continuing the ongoing therapy STI group performing long term CD4 guided structured treatment interruptions In the STI arm patients will stay off therapy until their CD4 count will drop \< 350 cells/mcL (one measurement will be considered sufficient). At that time point patients will resume the HAART regimen they were assuming before STI and will continue HAART until they CD4 count will raise \> 600 cells/mcL (at least 2 consecutive measurements 2 months apart) and their HIV-RNA will drop below the detection limit of 50 copies/ml (one measurement will be considered sufficient). When both the CD4 count and the viral load will be within these pre-set values they will stop therapy again. There is no limit to the number of interruptions and re-start cycles during the study period End points: The primary end-point for the evaluation of the main objective of the study will be clinical. The primary outcome measure will be based on the occurrence of a clinical end-point defined as: disease progression (occurrence of any AIDS defining event), death for any cause or the occurrence of clinical events requiring hospital admission The secondary objectives of the study will be evaluated on the basis of:
• Mean variation of blood cholesterol and triglycerides from baseline values.
• Development of lipodystrophy or modification of a pre-existing lipodystrophy
• Time off therapy.
• Variation of CD4 counts and HIV-RNA levels
• Genotypic tests to be performed in the case of HIV-RNA \> 1000 copies/ml while on therapy for at least 4 months or one month after each treatment interruption. Statistics: The study is powered to evaluate equivalence between the two strategies under the assumption that, in the control arm, the primary end-point would be observed in a proportion of subjects \< 7% and that the same proportion in the STI arm would not exceed 10% with a maximum allowed 95%CI of 12%. 320 patients will be needed for alfa = 5% and 1-beta = 80%. The primary analysis will be made according to the intention-to-treat approach and therefore no correction for eventual drop outs is needed. In addition, a secondary per-protocol analysis will be performed.

Conditions

HIV Infections; AIDS

Keywords

STI; HIV; CD4; HIV-RNA; HAART

Outcome Measures

Primary Outcomes (1)

• The primary outcome will be clinical response: Death, ADE, pathology requiring hospital admission

  5 years

Secondary Outcomes (3)

• Mean variation of blood cholesterol and triglycerides from baseline values. Development of lipodystrophy or modification of a pre-existing lipodystrophy

  5 years

• Time off therapy, variation of CD4 counts and HIV-RNA levels

  5 years

• Genotypic tests to be performed in the case of HIV-RNA > 1000 copies/ml while on therapy for at least 4 months or one month after each treatment interruption.

  5 years

Study Arms (2)

1

EXPERIMENTAL

STI

Other: STI

2

ACTIVE COMPARATOR

stable HAART, Any registered regimen containing NRTIs (AZT or D4T or 3TC or TDF or DDI), NNRTIs (EFV or NVP) or PIs (RTV-boosted ATV; IDV; LPV, fosAPV, SQV; unboosted ATV or NFV)is allowed according to international guidelines

Drug: stable HAART

Interventions

STI OTHER

CD4 guided treatment interruption

1

stable HAART DRUG

continuous therapy

2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \> 17 years
• Informed consent signed
• Effective ongoing treatment (HIV-RNA \< 50 copies/ml). Treatment must be based on any triple drug therapy. Patients must be on the same steady therapy for at least 3 months.
• Current CD4 cell count above 600 cells/mcL and nadir of CD4 cell count \> 200 cells/mcL

You may not qualify if:

• Childbearing or breastfeeding. Women of childbearing potential will be asked to adopt effective contraceptive methods or behaviors
• Previous diagnosis of AIDS
• Patients with HBV coinfection on active anti-HIV treatment with either lamivudine and/or tenofovir

Sponsors & Collaborators

• A.O. Ospedale Papa Giovanni XXIII: lead

Study Sites (1)

Ospedali Riuniti

Bergamo, BG, 24128, Italy

Location

MeSH Terms

Conditions

HIV Infections; Acquired Immunodeficiency Syndrome; Sexually Transmitted Diseases

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Slow Virus Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Franco Maggiolo, MD

  Ospedali Riuniti, Bergamo

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: February 7, 2007
• First Posted: February 9, 2007
• Study Start: January 1, 2004
• Last Updated: April 25, 2008

Record last verified: 2008-04

Locations

IT (1)